

# sentinel<sup>®</sup> spectrum<sup>®</sup> chews (milbemycin oxime-lufenuron-praziquantel)

**Caution:** Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian.

**Description:** SENTINEL<sup>®</sup> SPECTRUM<sup>®</sup> Chews are available in four strengths in color-coded packages for oral administration to dogs and puppies according to their weight. Each chewable tablet contains the following active ingredients in a minimum of 0.23 mg/mg (0.5 mg/kg) of milbemycin oxime, 4.55 mg/mg (10mg/kg) of lufenuron, and 2.28 mg/mg (5mg/kg) of praziquantel.

Milbemycin oxime consists of the oxime derivative of 5-dihydrothiophenyl in the ratio of approximately 80% A, C<sub>21</sub>H<sub>24</sub>N<sub>2</sub>O<sub>2</sub>, MW 355.71) and 20% A, C<sub>21</sub>H<sub>24</sub>N<sub>2</sub>O<sub>2</sub>, MW 361.68. Milbemycin oxime is classified as a macrocyclic anthelmintic.

Lufenuron is a benzophenylene derivative with the following chemical composition: N-[2-(5-dichloro-4-(1',1',2,3,3',3'-hexafluoroisopropoxy)-phenyl-aminocarbonyl)-6-(2-difluorobenzyloxy)ethyl]acetamide, MW 511.15. Benzophenylene compounds, including lufenuron, are classified as insect growth inhibitors (IGIs).

Praziquantel is an isoxazole anthelmintic with the chemical name 2-(5-chloro-1-pyridin-2-yl-1,2,3,6,7-tetrahydro-4H-pyridazin-4-yl)-1H-imidazo[4,5-b]pyridine-4-one.

**Indications:** SENTINEL SPECTRUM Chews are indicated for the prevention of heartworm disease caused by *Dirofilaria immitis* for the prevention and control of flea populations (*Ctenocephales felis*) and for the treatment and control of adult roundworm (*Toxascaris canis*, *Toxascaris leonina*, adult hookworm (*Ancylostoma caninum*, adult whipworm (*Trichuris vulpis*) and adult *Banana* *paratoma*, *Echinococcus multilocularis* and *Echinococcus granulosus*) infections in dogs and puppies two pounds up to body weight or greater and six weeks of age and older.

**Dosage and Administration:** SENTINEL SPECTRUM Chews should be administered orally, once every month, at the minimum dosage of 0.23 mg/lb (0.5 mg/kg) milbemycin oxime, 4.55 mg/lb (10 mg/kg) lufenuron, and 2.28 mg/lb (5 mg/kg) praziquantel for heartworm prevention, give once monthly for at least 6 months after exposure to mosquitoes (see **EFFECTIVENESS**).

Dosage Schedule				
Milbemycin Oxime per Chewable	Lufenuron per Chewable	Praziquantel per Chewable	Number of Chewables	
2 to 25 lbs.	2.3 mg	46 mg	23 mg	One
8.1 to 25 lbs.	5.75 mg	115 mg	57 mg	One
25.1 to 50 lbs.	11.5 mg	230 mg	114 mg	One
50.1 to 100 lbs.	23.0 mg	460 mg	228 mg	One
Over 100 lbs. Administer the appropriate combination of chewables				

To ensure adequate absorption, always administer SENTINEL SPECTRUM Chews to dogs immediately after or in conjunction with a normal meal.

SENTINEL SPECTRUM Chews may be offered to the dog by hand or added to a small amount of dog food. The chewables should be administered to a dog in a manner that encourages the dog to chew rather than to swallow without chewing. Chewables may be broken into pieces and fed to dogs that normally swallow treats whole. Care should be taken that the dog consumes the complete dose, and treated animals should be observed a few minutes after administration to ensure that the part of the dose is not rejected. If it is suspected that any of the dose has been lost, re-dosing is recommended.

**Heartworm Prevention:** SENTINEL SPECTRUM Chews should be administered at monthly intervals beginning within one month of the dog's first seasonal exposure to mosquitoes and continuing until at least 6 months after the dog's last seasonal exposure (see **EFFECTIVENESS**). SENTINEL SPECTRUM Chews may be administered year-round without interruption. When administering heartworm prevention to a dog with a normal product to SENTINEL SPECTRUM Chews, the first dose of SENTINEL SPECTRUM Chews should be given within a month of the last dose of the former product.

**Flea Treatment and Prevention:** Treatment with SENTINEL SPECTRUM Chews may begin at any time of the year. If fleas are already starting one month before fleas become active and continuing monthly through the end of flea season. In areas where fleas are common year-round, monthly treatment with SENTINEL SPECTRUM Chews should continue for the entire year without interruption.

To minimize the likelihood of flea reinfestation, it is important to treat all animals within a household with an approved flea protection product, as necessary.

**Intestinal Nematode and Cestode Treatment and Control:** Dogs may be exposed to and can become infected with roundworms, whipworms, hookworms, and tapeworms throughout the year, regardless of season or climate. Clients should be advised of appropriate measures to prevent reinfestation of their dog with intestinal parasites. Because the prepatent period for *E. multilocularis* and *E. granulosus* in dogs is 26 days, dogs treated at the labeled monthly intervals may become reinfested and shed eggs between treatments.

**Contraindications:** There are no known contraindications to the use of SENTINEL SPECTRUM Chews.

**Warnings:** Not for use in humans. Keep this and all drugs out of the reach of children.

**Precautions:** Treatment with fewer than 6 monthly doses after the last exposure to mosquitoes may not provide complete heartworm prevention (see **EFFECTIVENESS**). SENTINEL SPECTRUM Chews, dogs should be tested for existing heartworm infection. Prior to administration of SENTINEL SPECTRUM Chews, dogs should be tested for existing adult heartworms. SENTINEL SPECTRUM Chews are not effective against adult *D. immitis*.

Mild, transient hypersensitivity reactions, such as altered breathing, vomiting, hypersalivation, and lethargy have been noted in some dogs treated with milbemycin oxime carrying a high number of circulating microfilariae. These reactions are presumably caused by release of protein from dead or dying microfilariae.

Do not use in puppies less than six weeks of age.

Do not use in dogs or puppies less than two pounds of body weight.

The safety of SENTINEL<sup>®</sup> SPECTRUM<sup>®</sup> Chews has not been evaluated in dogs used for breeding or in lactating females. Studies have been performed with milbemycin oxime and lufenuron (see **ANIMAL SAFETY**).

**Adverse Reactions:** The following adverse reactions have been reported in dogs after administration of milbemycin oxime, lufenuron, or praziquantel: vomiting, depression/lethargy, pruritus, urticaria, diarrhea, anorexia, skin congestion, alopecia, convulsions, salivation, and weakness.

To report suspected adverse drug events, contact Merck Animal Health at 1-800-224-5318. For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDA-VETS or <http://www.fda.gov/oc/medwatch>.

For technical assistance, contact Merck Animal Health at 1-800-224-5318.

**Information for Owner or Person Treating Animal:** *Echinococcus multilocularis* and *Echinococcus granulosus* are tapeworms found in wild canids and domestic dogs. *E. multilocularis* and *E. granulosus* can infect humans and cause serious disease (larval hydatid disease and hydatid disease, respectively). Owners of dogs living in areas where *E. multilocularis* or *E. granulosus* are endemic should be instructed on how to minimize their risk of exposure to these parasites, as well as their dog's risk of exposure. Although SENTINEL SPECTRUM Chews were 100% effective in laboratory studies in dogs against *E. multilocularis* and *E. granulosus*, no studies have been conducted to show that the use of this product will decrease the incidence of larval hydatid disease or hydatid disease in humans. Because the prepatent period for *E. multilocularis* may be as short as 26 days, dogs treated at the labeled monthly intervals may become reinfested and shed eggs between treatments.

## Efficiveness

**Heartworm Prevention:** In a well-controlled laboratory study, SENTINEL SPECTRUM Chews (milbemycin oxime, lufenuron, praziquantel) were 100% effective against induced heartworm infections when administered once monthly for 6 consecutive months. In well-controlled laboratory studies, neither one dose nor two consecutive doses of SENTINEL SPECTRUM Chews provided 100% effectiveness against induced heartworm infections.

**Intestinal Nematodes and Cestodes Treatment and Control:** Elimination of the adult stage of hookworm (*Ancylostoma caninum*, roundworm (*Toxascaris canis*, *Toxascaris leonina*, whipworm (*Trichuris vulpis*) and tapeworm (*Dipylidium caninum*, *Echinococcus multilocularis*, *Echinococcus granulosus*, *Banana paratoma*) infections in dogs was demonstrated in well-controlled laboratory studies.

**Flea Prevention and Control:** In well-controlled studies, SENTINEL SPECTRUM Chews were effective in preventing flea eggs from hatching, thus providing control of the development of flea populations (*Ctenocephales felis*).

**Palatability:** In a field study of 117 dogs offered SENTINEL SPECTRUM Chews, 113 dogs (96.6%) accepted the product when offered from the hand as if treat. 2 dogs (1.7%) accepted it from the bowl with food, 1 dog (0.9%) accepted it when it was placed in the dog's mouth, and 1 dog (0.9%) refused it.

**Animal Safety:** In a margin of safety study, 40 ten-week-old puppies (10 per group) were administered either a sham dose (0X or doses of 1, 3, or 5X the maximum exposure dose of SENTINEL SPECTRUM Chews once every two weeks for a total of seven treatments). Transient alopecia, lethargy, tremors, and salivation were seen in the 3X and 5X groups following each of the seven doses. Lethargy and alopecia were occasionally reported in sham-treated (0X) and 1X dogs. Tremors were observed below post-treatment in the 1X treatment group. Vomiting was seen in all treatment groups but at a higher incidence in the 3X and 5X groups. At the 5X dose, shallow breathing was noted in two dogs and one dog was unable to stand following two different doses. All clinical signs resolved within 24 hours.

In a second margin of safety study, 64 six-week-old puppies (16 per group) were dosed with either a sham (0X or 1, 3, or 5X the maximum exposure dose of SENTINEL SPECTRUM Chews on days 1, 5, 29, and 43. A dose dependent increase in alopecia, decreased activity, tremors, and salivation was seen within 24 hours of treatment. Salivary gland inflammation was observed once in one dog in the 5X treatment group. Vomiting was observed in the 5X treatment group.

For SENTINEL SPECTRUM Chews, the maximum exposure based on product dosing is 2.5 mg/kg for milbemycin oxime, 25.7 mg/kg for lufenuron and 25.1 mg/kg for praziquantel, which is 1.6 higher than the minimum effective dose used in the safety studies for milbemycin oxime and lufenuron (see below).

302298-02 - 5/17/2010

# sentinel<sup>®</sup> flavor tabs<sup>®</sup> (milbemycin oxime-lufenuron)

The palatable one-a-month prescription tablet that prevents heartworm disease and flea populations in dogs and puppies. SENTINEL<sup>®</sup> FLAVOR TABS<sup>®</sup> (milbemycin oxime/lufenuron) also control flea populations and adult hookworms, and remove and control adult roundworm and whipworm infections in dogs and puppies.

**Caution:** Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian.

## Warnings

Not for human use. Keep this and all drugs out of the reach of children.

## Description

SENTINEL FLAVOR TABS are available in four tablet sizes in color-coded packages for oral administration to dogs and puppies according to their weight. (See Dosage Section). Each tablet is formulated to provide a minimum of 0.23 mg/pound (0.5 mg/kg) of milbemycin oxime and 4.55 mg/pound (10 mg/kg) body weight of lufenuron.

Milbemycin oxime consists of the oxime derivatives of 5-dihydrothiophenyl in the ratio of approximately 80% A, C<sub>21</sub>H<sub>24</sub>N<sub>2</sub>O<sub>2</sub>, MW 355.71) and 20% A, C<sub>21</sub>H<sub>24</sub>N<sub>2</sub>O<sub>2</sub>, MW 361.68. Milbemycin oxime is classified as a macrocyclic anthelmintic.

A margin-of-safety study conducted in rough-coated Collies resulted in alopecia, pyrexia, and periodic recumbency in one of fourteen dogs administered milbemycin oxime at 12.5 mg/kg (8X the maximum exposure dose of SENTINEL SPECTRUM Chews). Prior to receiving the 12.5 mg/kg dose on day 56 of the study, all animals had undergone a daily regimen consisting of 2.5 mg/kg milbemycin oxime for 10 days, followed by 5.0 mg/kg on day 14, and 10.0 mg/kg on day 32. No adverse reactions were observed in any of the Collies treated with doses less than 12.5 mg/kg.

Lufenuron is a benzophenylene derivative with the following chemical composition: N-[2-(5-dichloro-4-(1',1',2,3,3',3'-hexafluoroisopropoxy)-phenyl-aminocarbonyl)-2-(6-difluorobenzyloxy)ethyl]acetamide, MW 511.15. Benzophenylene compounds, including lufenuron, are classified as insect development inhibitors (IDIs).

**Mode of Action**

Milbemycin oxime, an active ingredient in SENTINEL FLAVOR TABS, is a macrocyclic anthelmintic which is believed to act by interfering with invertebrate neurotransmission. Milbemycin oxime eliminates the tissue stage of heartworm larvae and the adult stage of hookworm (*Ancylostoma caninum*, roundworm (*Toxascaris canis* and *Toxascaris leonina*) and whipworm (*Trichuris vulpis*) infestations when administered orally according to the recommended dosage schedule.

Lufenuron, the other active ingredient in SENTINEL FLAVOR TABS, is an insect development inhibitor which breaks the flea life cycle by inhibiting egg development. Lufenuron's mode of action is interference with chitin synthesis, polymerization and deposition. Lufenuron has no effect on the adult flea. After biting a lufenuron-treated dog, the female flea ingests a blood meal containing lufenuron which is subsequently deposited in the eggs. Lufenuron prevents the maturation of flea eggs from hatching and maturing into adults and thus prevents and controls flea populations by breaking the life cycle. (See Efficacy).

## Indications

SENTINEL FLAVOR TABS are indicated for use in dogs and puppies, four weeks of age and older, and two pounds body weight or greater. SENTINEL FLAVOR TABS are also indicated for the prevention of heartworm disease caused by *Dirofilaria immitis*, for the prevention and control of flea populations, the control of adult *Ancylostoma caninum* (hookworm), and the removal and control of adult *Toxascaris canis* and *Toxascaris leonina* (roundworm) and *Trichuris vulpis* (whipworm) infections.

Lufenuron controls flea populations by preventing the development of flea eggs and does not kill adult fleas. Concurrent use of an adulticide product may be necessary for adequate control of adult fleas.

**Without concurrent use of an adulticide, adequate flea control may not be achieved in dogs that have repeated exposure to flea infested animals or environments.**

## Precautions

Do not use in puppies less than four weeks of age and less than two pounds of body weight. Prior to administration of SENTINEL FLAVOR TABS, dogs should be tested for existing heartworm infections. Infected dogs should be treated to remove adult heartworms and microfilariae prior to initiating treatment with SENTINEL FLAVOR TABS. Mild, transient hypersensitivity reactions manifested as labored respiration, vomiting, salivation and lethargy have been noted in some treated dogs carrying a high number of circulating microfilariae. These reactions are presumably caused by release of protein from dead or dying microfilariae.

SENTINEL FLAVOR TABS immediately break the flea life cycle by inhibiting egg development. However, persisting flea populations may continue to develop and emerge after treatment with SENTINEL FLAVOR TABS has begun. Based on results of clinical studies, this emergence generally occurs during the first 30-60 days.

Therefore, noticeable control may not be observed until several weeks after dosing when a preexisting infestation is present. Cooler geographic areas may have longer lag periods due to a prolonged flea life cycle. The concurrent use of an approved adulticide may be employed depending on the severity of the infestation.

If a SENTINEL FLAVOR TABS-treated dog comes in contact with a flea-infested environment, adult fleas may infest the treated animal. These adult fleas are unable to produce viable offspring. The temporary use of an adulticide product may be necessary to kill these adult fleas.

## Efficacy: Milbemycin Oxime

Milbemycin oxime provided complete protection against heartworm infection in both controlled laboratory and clinical trials. In laboratory studies, a single dose of milbemycin oxime at 0.5 mg/kg was effective in removing roundworms, hookworms and whipworms. In well-controlled clinical trials, milbemycin oxime was also effective in removing roundworms and whipworms and in controlling hookworms.

## Efficacy: Lufenuron

Lufenuron provided 99% control of flea egg development for 32 days following a single dose of lufenuron at 10 mg/kg in two experimental flea infestations. In well-controlled clinical trials, when treatment with lufenuron tablets was initiated prior to the flea season, mean flea counts were lower on lufenuron-treated dogs versus placebo-treated dogs. After 6 monthly treatments, the mean number of fleas on lufenuron-treated dogs was approximately 4 compared to 220 on placebo-treated dogs. When treatment was initiated during the flea season, lufenuron tablets were effective in controlling flea infestations on dogs that completed the study. The mean flea count per lufenuron-treated dog was approximately 74 prior to treatment but had decreased to 4 after six monthly doses of lufenuron. A topical adulticide was used in the first eight weeks of the study to kill the pre-existing adult fleas.

## Safety: Milbemycin Oxime

Milbemycin oxime has been tested safely in over 75 different breeds of dogs, including collies, prelay, prelay females, breeding males and females, and puppies over two weeks of age. In well-controlled clinical field studies 786 dogs completed treatment with milbemycin oxime. Milbemycin oxime was used safely in animals receiving frequently used veterinary products such as vaccines, anthelmintics, antibiotics, steroids, flea collars, shampoos and dips.

Two studies in heartworm-infected dogs were conducted which demonstrated mild, transient hypersensitivity reactions in treated dogs with high microfilaraemia counts (see Precautions for reactions observed). Safety studies in pregnant dogs demonstrated that high doses (1.5 mg/kg – 2X) of milbemycin oxime given in an exaggerated dosing regimen (daily from mating through weaning), resulted in measurable concentrations of the drug in milk. Puppies nursing these females which received exaggerated dosing regimens demonstrated milbemycin-related effects. These effects were directly attributable to the exaggerated-experimental dosing regimen. The product is normally intended for once-a-month administration only. Subsequent studies included using 3X daily from mating to one week before weaning and demonstrated no effects on the pregnant females or their litters. A second study where pregnant females were dosed once at 3X the monthly use rate before, on the day of or shortly after whelping resulted in no effects on the puppies.

Some nursing puppies, at 2, 4, and 6 weeks of age, given greatly exaggerated oral doses of milbemycin oxime (9.6 mg/kg = 19X) exhibited signs typified by tremors, vocalization and alopecia. These effects were all transient and puppies returned to normal within 24 to 48 hours. No effects were observed in puppies given the recommended dose of milbemycin oxime (0.5 mg/kg). This product has not been tested in dogs less than 2.2 pounds in body weight.

A rising-dose safety study conducted in rough-coated collies manifested a clinical reaction consisting of alopecia, pyrexia and periodic recumbency in one of fourteen dogs treated with milbemycin oxime at 12.5 mg/kg (8X monthly use rate). Prior to receiving the 12.5 mg/kg dose (25X monthly use rate) on day 56 of the study, all animals had undergone an exaggerated dosing regimen consisting of 2.5 mg/kg milbemycin oxime (5X monthly use rate) on day 0, followed by 5.0 mg/kg (10X monthly use rate) on day 14 and 10.0 mg/kg (20X monthly use rate) on day 32. No adverse reactions were observed in any of the collies treated with this regimen up through the 10.0 mg/kg (20X monthly use rate) dose.

**Safety: Lufenuron**

Lufenuron tablets have been used and tested safely in over forty breeds of dogs, including pregnant females, breeding males and puppies over six weeks of age. In well-controlled clinical trials, 151 dogs concurrent administration of lufenuron tablets. Lufenuron tablets were used safely in animals receiving frequently used veterinary products such as vaccines, anthelmintics, antibiotics and steroids. In a ten-month study, doses up to 10X the recommended dose rate of 10 mg/kg caused no overt toxicity. A single dose of 200 mg/kg (20X the recommended dose rate) had no marked effect on adult dogs, but caused decreased activity and appetite in eight week old puppies. Mean body weights of male and female puppies were higher in treated versus control group at the end of the study. In specifically designed target animal safety studies, lufenuron tablets were tested concurrent administration of flea adulticides containing carbaryl, permethrin, chlorpyrifos and cyfluthrin. No toxicity resulted from these combinations. Lufenuron tablets did not cause cholinesterase inhibition nor did they enhance cholinesterase inhibition caused by exposure to organophosphates.

Four reproductive safety studies were conducted in breeding dogs with lufenuron treated and two laboratory and two well-controlled clinical studies. In one of the laboratory studies, where lufenuron was administered to beagle dogs at doses equivalent to 90X (3X daily) the monthly recommended dose of 10 mg/kg, the ratio of gravid females to females mated was 8/8 or 100% in the control group and 6/8 or 67% in the lufenuron-treated group. The mean number of pups per litter was two animals higher in the treated versus control group and the mean birth weights of pups from treated females in this study was lower than control groups.

These pups grew at a similar rate to control pups. There was a higher incidence of four clinical signs in the lufenuron-treated versus control group; nasal discharge, primary constipation, diarrhea/dehydration and sluggishness. The incidence of these signs was transient and decreasing by the end of lactation. Results from three additional reproductive safety studies, one laboratory and two clinical field studies evaluating eleven breeds of dogs, did not demonstrate any adverse findings for the reproductive parameters measured including fertility, pup birth weights and pup clinical signs after administration of lufenuron up to 5X the recommended monthly use rate.

Data from analysis of milk from lactating animals treated with lufenuron tablets at 2X and 6X, the recommended monthly use rate demonstrates that lufenuron concentrates in the milk of these dogs. The average milk blood concentration ratio was approximately 60:1. 60X higher drug concentrations in the milk compared to drug levels in the blood of treated females). Nursing puppies averaged 8-9 times higher milk blood concentrations of lufenuron compared to their dams.

These pups grew at a similar rate to control pups. There was a higher incidence of four clinical signs in the lufenuron-treated versus control group; nasal discharge, primary constipation, diarrhea/dehydration and sluggishness. The incidence of these signs was transient and decreasing by the end of lactation. Results from three additional reproductive safety studies, one laboratory and two clinical field studies evaluating eleven breeds of dogs, did not demonstrate any adverse findings for the reproductive parameters measured including fertility, pup birth weights and pup clinical signs after administration of lufenuron up to 5X the recommended monthly use rate.

Data from analysis of milk from lactating animals treated with lufenuron tablets at 2X and 6X, the recommended monthly use rate demonstrates that lufenuron concentrates in the milk of these dogs. The average milk blood concentration ratio was approximately 60:1. 60X higher drug concentrations in the milk compared to drug levels in the blood of treated females). Nursing puppies averaged 8-9 times higher milk blood concentrations of lufenuron compared to their dams.

**Dosage**

SENTINEL FLAVOR TABS are given orally, once a month, at the recommended minimum dosage of 0.23 mg/lb (0.5 mg/kg) milbemycin oxime and 4.55 mg/lb (10mg/kg) lufenuron. Dogs over 100 lbs are provided the appropriate combination of tablets.

## Administration

TO ENSURE ADEQUATE ABSORPTION, ALWAYS ADMINISTER SENTINEL FLAVOR TABS TO DOGS IMMEDIATELY AFTER OR IN CONJUNCTION WITH A NORMAL MEAL.

## SENTINEL FLAVOR TABS

are palatable and most dogs will consume the tablet when offered by the owner.

As an alternative to direct dosing, the tablets can be hidden in food. Be certain the dog consumes the entire tablet or tablets.

Administer SENTINEL FLAVOR TABS to dogs immediately after or in conjunction with a normal meal. Food is essential for adequate absorption of lufenuron. Watch the dog closely following administration to be sure the entire dose has been consumed. If it is not entirely consumed, redose with the full recommended dose as soon as possible.

SENTINEL FLAVOR TABS must be administered monthly, preferably on the same date each month. Treatment with SENTINEL FLAVOR TABS may begin at any time of year. In geographic areas where mosquitoes and fleas are seasonal, the treatment schedule should begin one month prior to the expected onset and should continue until the end of "mosquito and flea season." In areas with year-round infestations, treatment should continue through the entire year without interruption.

If a dog is missed and a 30-day interval between dosing is exceeded, administer SENTINEL FLAVOR TABS immediately and resume the monthly dosing schedule. If SENTINEL FLAVOR TABS replace daily diethylcarbamazine (DEC) for heartworm prevention, the first dose must be given within 30 days after the last dose of DEC.

## Adverse Reactions

The following adverse reactions have been reported in dogs after giving milbemycin oxime or lufenuron: vomiting, depression/lethargy, pruritus, urticaria, diarrhea, anorexia, skin congestion, alopecia, convulsions, hypersalivation, and weakness.

To report suspected adverse drug events, contact Merck Animal Health at 1-800-224-5318. For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDA-VETS or <http://www.fda.gov/oc/medwatch>.

## How Supplied

SENTINEL FLAVOR TABS are available in four tablet sizes (see Dosage section) formulated according to the weight of the dog. Each tablet size is available in color-coded packages of 6 or 12 tablets each, which are packaged 10 per display carton.

## Storage Conditions

Store in a dry place at controlled room temperature, between 59° and 77°F (15-25°C).

## Questions? Comments?

Please Call 1-800-224-5318

Visit our website at SentinelPet.com

## Manufactured by:

Intervet Inc. (a/b/a Merck Animal Health)

2 Grindas Farms

Madison, NJ 07940

Approved by FDA under NADA # 141-084

© 2019, 2020 Intervet Inc., a subsidiary of Merck and Co., Inc. All Rights Reserved.

Rev. 07/20



# A SPECTRUM OF PROTECTION

# A FRIENDSHIP FREE FROM PARASITES

- Protect against unseen<sup>®</sup> threats
- with SENTINEL<sup>®</sup> SPECTRUM<sup>®</sup> Chews.



\*SENTINEL SPECTRUM Chews protects against heartworm disease, 4 intestinal parasites, and prevents flea eggs from hatching.



YOU MAY NOT  
SEE THEM, BUT  
YOU CAN PROTECT  
AGAINST THEM



**SENTINEL SPECTRUM Chews provides broad-spectrum protection against 6 types of parasites.¹**

From head to tail, your dog needs protection from parasites that you do not see. That's why it's so important to protect them with SENTINEL SPECTRUM Chews.



\*A. caninum.  
\*Prevents flea eggs from hatching.

PROVEN  
TO BE SAFE  
PROVEN TO  
BE DELICIOUS



SENTINEL SPECTRUM Chews has been shown to be safe for puppies as young as 6 weeks of age.<sup>1</sup>



Dogs love the beef and bacon flavor<sup>2</sup> of SENTINEL SPECTRUM Chews.



**NEVER FORGET  
A DOSE**

Remember to protect your dog  
all year round



**1 CHEW  
EVERY  
30 DAYS**

**IMPORTANT SAFETY INFORMATION:**

**SENTINEL® SPECTRUM® Chews (milbemycin oxime/lufenuron/praziquantel).** Dogs should be tested for heartworm prior to use. Mild hypersensitivity reactions have been noted in some dogs carrying a high number of circulating microfilariae. Treatment with fewer than 6 monthly doses after the last exposure to mosquitoes may not provide complete heartworm prevention. See reverse side for full product information.

**SENTINEL® FLAVOR TABS® (milbemycin oxime/lufenuron).** Dogs should be tested for heartworm prior to use. In a small percentage of treated dogs, digestive, neurologic, and skin side effects may occur. See reverse side for full product information.

Reference: 1. SENTINEL® SPECTRUM® Chews [product label]. Madison, NJ: Intervet, Inc.; 2020. 2. Data on file. Merck Animal Health. 3. SENTINEL® FLAVOR TABS® [product label]. Madison, NJ: Intervet, Inc.; 2020.



**You've got options**

With SENTINEL® FLAVOR TABS®, you have an alternative that protects against 5 types of parasites.<sup>3</sup>

